dihexa human studies clinical trials DHX / PNB-0408 Dihexa, nuBioAge Enhance Cognitive Function

Our peptides are backed by verified COA, ensuring researchers can trust in their efficacy and safety

By targeting beta-3 adrenergic receptors in adipose tissue and initiating metabolic cascades that enhance fat breakdown, this growth hormone fragment provides fat-reducing benefits without affecting glucose metabolism, insulin sensitivity, or IGF-1 production

Phase 2 & 3 trial data: up to 28.7% weight loss at 12 mg

Mild redness or irritation may occur at the injection site in some cases Temporary sensitivity can be experienced, especially in first sessions Not suitable for everyone, including certain medical conditions without evaluation Requires administration by trained professionals to avoid complications Unregulated or non clinical sources may increase risks significantly Overuse without supervision is not recommended Consultation helps identify suitability and expected outcomes How GHK Cu Injection Is Given The method of administration is an important factor in achieving safe and effective results